title: Targeting inhibitory pathways in cancer immunotherapy.
abstract: The clinical success of adaptive transfer of in vitro expanded antigen-specific CD8(+) T cells isolated from patients' tumors has demonstrated that effector cells of the adaptive immune system can effectively eliminate even large tumor masses. Nevertheless, cancer vaccines that aim to expand such CD8(+) T cells in situ have had remarkably little success in spite of numerous attempts. Recent advances in basic immunology have revealed layers of complexity controlling activation and maintenance of adaptive immune responses that are tightly controlled by immunoinhibitory pathways to avoid horror autotoxicus. During tumor progression the activities of negative pathways increase and together with cancer immune evasion tactics presumably prevent induction of an efficacious immune response by cancer vaccines that solely provide more antigen to an already suppressed system. Cancer vaccines may thus need to readjust the imbalance of the cancer patients' immune system by inhibiting immunoinhibitors; such regimens have shown preclinical efficacy and are now entering clinical trials hopefully ending the Kafkaesque futility of cancer vaccines.
authors.affiliation: The Wistar Institute, Philadelphia, PA 19104, USA. mlasaro@wistar.org
authors.forename: Marcio O
authors.initials: MO
authors.lastname: Lasaro
authors.forename: Hildegund C J
authors.initials: HC
authors.lastname: Ertl
mesh_terms: D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D051379:Mice; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D019139:Tumor Escape / Q000276:immunology*
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines
references.citation: J Exp Med. 2004 Dec 20;200(12):1613-22
references.pmid: 15611289
references.citation: J Clin Oncol. 2009 Sep 1;27(25):4035-7
references.pmid: 19635998
references.citation: J Exp Med. 1997 Jul 21;186(2):229-38
references.pmid: 9221752
references.citation: Immunol Today. 1997 Jun;18(6):292-9
references.pmid: 9190116
references.citation: Cancer Immunol Immunother. 2009 Mar;58(3):317-24
references.pmid: 18704409
references.citation: Mech Ageing Dev. 2009 Oct;130(10):709-12
references.pmid: 19715717
references.citation: Cell Immunol. 1983 Oct 15;81(2):298-305
references.pmid: 6605806
references.citation: Cytokine. 2000 Jun;12(6):547-54
references.pmid: 10843728
references.citation: Ageing Res Rev. 2004 Jan;3(1):15-29
references.pmid: 15163101
references.citation: Hum Immunol. 2008 Apr-May;69(4-5):241-9
references.pmid: 18486758
references.citation: J Leukoc Biol. 2010 Feb;87(2):223-35
references.pmid: 20007250
references.citation: Nat Immunol. 2008 Feb;9(2):176-85
references.pmid: 18193050
references.citation: Immunol Res. 2001;23(2-3):263-72
references.pmid: 11444391
references.citation: Nat Rev Microbiol. 2010 Jan;8(1):62-73
references.pmid: 19966816
references.citation: Lancet. 2007 Jun 2;369(9576):1861-1868
references.pmid: 17544766
references.citation: Nat Immunol. 2009 Jan;10(1):29-37
references.pmid: 19043418
references.citation: J Clin Oncol. 2005 Apr 1;23(10):2346-57
references.pmid: 15800326
references.citation: Immunol Rev. 2008 Aug;224:141-65
references.pmid: 18759925
references.citation: Clin Exp Immunol. 2005 Jun;140(3):540-6
references.pmid: 15932517
references.citation: Curr Opin Immunol. 2009 Aug;21(4):418-24
references.pmid: 19570667
references.citation: Immunol Lett. 2006 Jun 15;105(2):115-22
references.pmid: 16580736
references.citation: Curr Mol Med. 2009 Aug;9(6):725-31
references.pmid: 19689299
references.citation: N Engl J Med. 2009 Nov 5;361(19):1838-47
references.pmid: 19890126
references.citation: Semin Cancer Biol. 2002 Feb;12(1):43-50
references.pmid: 11926411
references.citation: World J Gastroenterol. 2009 Feb 7;15(5):513-20
references.pmid: 19195051
references.citation: J Natl Cancer Inst. 2009 Oct 7;101(19):1348-55
references.pmid: 19759364
references.citation: Cancer Sci. 2009 Aug;100(8):1389-96
references.pmid: 19459853
references.citation: J Pathol. 2005 Jan;205(2):181-93
references.pmid: 15641017
references.citation: Nat Rev Immunol. 2007 May;7(5):391-401
references.pmid: 17457345
references.citation: J Immunol. 2010 May 15;184(10):5475-84
references.pmid: 20410485
references.citation: Ann N Y Acad Sci. 2009 Sep;1174:99-106
references.pmid: 19769742
references.citation: J Exp Med. 2008 Mar 17;205(3):711-23
references.pmid: 18332179
references.citation: Nat Rev Immunol. 2008 Jun;8(6):467-77
references.pmid: 18500231
references.citation: J Clin Invest. 2007 Nov;117(11):3383-92
references.pmid: 17932562
references.citation: J Immunol. 2007 Feb 15;178(4):1975-9
references.pmid: 17277099
references.citation: Cancer J. 2009 May-Jun;15(3):169-73
references.pmid: 19556898
references.citation: Nat Med. 2008 Feb;14(2):205-12
references.pmid: 18193057
references.citation: Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5250-5
references.pmid: 17875752
references.citation: Curr Opin Immunol. 2007 Jun;19(3):309-14
references.pmid: 17433872
references.citation: Annu Rev Immunol. 2005;23:515-48
references.pmid: 15771580
references.citation: J Virol. 2003 Apr;77(8):4911-27
references.pmid: 12663797
references.citation: Int Immunol. 2007 Oct;19(10):1223-34
references.pmid: 17898045
references.citation: Hum Vaccin. 2009 Jan-Feb;5(1):6-14
references.pmid: 18927514
references.citation: Vaccine. 2000 Feb 25;18(16):1717-20
references.pmid: 10689155
references.citation: Cell. 1996 Nov 1;87(3):427-36
references.pmid: 8898196
references.citation: J Exp Med. 1996 Mar 1;183(3):959-70
references.pmid: 8642299
references.citation: Curr Opin Mol Ther. 2009 Feb;11(1):31-6
references.pmid: 19169957
references.citation: Cancer Res. 2010 Jan 1;70(1):109-18
references.pmid: 20028856
references.citation: Trends Mol Med. 2008 Dec;14(12):550-9
references.pmid: 18986838
references.citation: Exp Gerontol. 2009 Aug;44(8):517-22
references.pmid: 19457448
references.citation: J Immunol. 2008 May 15;180(10):6649-55
references.pmid: 18453584
references.citation: Front Biosci (Landmark Ed). 2009 Jan 01;14:1761-70
references.pmid: 19273160
references.citation: Semin Cancer Biol. 2007 Aug;17(4):317-29
references.pmid: 17651986
references.citation: Adv Immunol. 2006;90:297-339
references.pmid: 16730267
references.citation: Nat Immunol. 2005 Jan;6(1):90-8
references.pmid: 15568026
references.citation: Jpn J Clin Oncol. 2009 Feb;39(2):73-80
references.pmid: 19015149
references.citation: Curr Opin Immunol. 2004 Apr;16(2):143-50
references.pmid: 15023405
references.citation: Immunol Rev. 2009 May;229(1):145-51
references.pmid: 19426220
references.citation: Immunology. 2005 Jan;114(1):37-43
references.pmid: 15606793
references.citation: Mech Ageing Dev. 2009 Aug;130(8):509-17
references.pmid: 19540259
references.citation: J Clin Invest. 2007 May;117(5):1167-74
references.pmid: 17476346
references.citation: Adv Exp Med Biol. 1988;233:119-28
references.pmid: 3146901
references.citation: Immunol Res. 1999;20(2):101-8
references.pmid: 10580635
references.citation: Immunol Rev. 1997 Dec;160:63-77
references.pmid: 9476666